BiondVax Reports Second Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 08/11/23
BiondVax Announces First Quarter 2023 Financial Results and Provides Business UpdateAccesswire • 05/15/23
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business UpdateGlobeNewsWire • 04/17/23
BiondVax's Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo StudyGlobeNewsWire • 01/23/23
BiondVax's Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo StudyGlobeNewsWire • 01/06/23
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)Accesswire • 12/21/22
IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.GlobeNewsWire • 12/06/22
Professor Dr. Matthias Dobbelstein joins BiondVax's Scientific Advisory BoardGlobeNewsWire • 12/06/22
BiondVax announces Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/30/22
BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life SciencesGlobeNewsWire • 11/15/22
BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 ConferencePRNewsWire • 11/03/22